Philadelphia University + Thomas Jefferson University
Sidney Kimmel Medical College
Department of Dermatology & Cutaneous Biology

South, Andrew

< Back

Profile

Andrew P South, PhD

Andrew P. South, PhD

Contact Dr. South

Bluemle Life Sciences Building, Room 406
233 South Tenth Street
Philadelphia, PA 19107

(215) 955-1934

Publications

Most Recent Peer-Reviewed Publications

  1. Retraction: Gentamicin B1 is a minor gentamicin component with major nonsense mutation suppression activity (Proceedings of the National Academy of Sciences of the United States of America (2017) 114 (3479–3484) DOI: 10.1073/pnas.1620982114)
  2. Precision Medicine for Heritable Skin Diseases—The Paradigm of Epidermolysis Bullosa
  3. The genomic landscape of cutaneous SCC reveals drivers and a novel azathioprine associated mutational signature
  4. Reduced Microbial Diversity Is a Feature of Recessive Dystrophic Epidermolysis Bullosa-Involved Skin and Wounds
  5. Metformin clinical trial in HPV+ and HPV-head and neck squamous cell carcinoma: Impact on cancer cell apoptosis and immune infiltrate
  6. APOBEC mutation drives early-onset squamous cell carcinomas in recessive dystrophic epidermolysis bullosa
  7. The role of human papillomaviruses and polyomaviruses in BRAF-inhibitor induced cutaneous squamous cell carcinoma and benign squamoproliferative lesions
  8. First report of COL7A1 mutations in two patients with recessive dystrophic epidermolysis bullosa from Peru
  9. Seven novel COL7A1 mutations identified in patients with recessive dystrophic epidermolysis bullosa from Mexico
  10. Differential glucose requirement in skin homeostasis and injury identifies a therapeutic target for psoriasis article
  11. Extracellular Vesicles as Biomarkers for the Detection of a Tumor Marker Gene in Epidermolysis Bullosa-Associated Squamous Cell Carcinoma
  12. Preclinical comparison of proteasome and ubiquitin E1 enzyme inhibitors in cutaneous squamous cell carcinoma: The identification of mechanisms of differential sensitivity
  13. High concordance between clinical diagnosis of epidermolysis bullosa and immunofluorescence with a small, well-matched antibody panel
  14. Pro-Inflammatory Chemokines and Cytokines Dominate the Blister Fluid Molecular Signature in Patients with Epidermolysis Bullosa and Affect Leukocyte and Stem Cell Migration
  15. Amlexanox Enhances Premature Termination Codon Read-Through in COL7A1 and Expression of Full Length Type VII Collagen: Potential Therapy for Recessive Dystrophic Epidermolysis Bullosa
  16. Desmoglein 2 modulates extracellular vesicle release from squamous cell carcinoma keratinocytes
  17. Gentamicin B1 is a minor gentamicin component with major nonsense mutation suppression activity
  18. Targeted next-generation sequencing of TP53 in oral tongue carcinoma from non-smokers
  19. Cardiomyopathy diagnosed in the eldest child harbouring p.S24X mutation in JUP
  20. MEK Is a Therapeutic and Chemopreventative Target in Squamous Cell Carcinoma